UC Endocrinologist Nelson Watts Honored

Nelson Watts, MD, FACE, professor of medicine and director of the UC Bone Health and Osteoporosis Center, has been designated a Master in his specialty by the American College of Endocrinology.

The Master designation recognizes individuals who have demonstrated exceptional leadership and made significant contributions to endocrinology. Dr. Watts has contributed to more than 50 books and book chapters and more than 200 abstracts and articles in such journals as the

New England Journal of Medicine

and

Archives of Internal Medicine

.

A past president of both the American College of Endocrinology and the International Society of Clinical Endocrinology, Dr. Watts serves on the FDA's Advisory Committee for Endocrine and Metabolic Drugs is on the editorial boards of Osteoporosis International and the Journal of Clinical Densitometry.

Tags

Related Stories

1

Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December

December 12, 2025

This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.

2

Ohio nurses weigh in on proposed federal loan rule

December 12, 2025

Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.

3

New combination treatment improves multiple myeloma outcomes

December 11, 2025

The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.